36 results
Thumbnail

D2.02 - Clinically Relevant Cross-Reactivity Between Artemisia vulgaris and Bee Pollen: A New Paradigm in Postprandial Exercise-Induced Anaphylaxis

Thumbnail

D2.04 - PREVALENCE OF ALPHA-GAL SENSITIZATION IN PATIENTS WITH ARTHROPOD BITE REACTIONS, CHRONIC SPONTANEOUS URTICARIA AND GASTROINTESTINAL SYMPTOMS IN LA RIOJA (SPAIN). Introduction

Thumbnail

D2.06 - Clinical Characteristics of Reactions to Oral Food Challenges with Egg- and Milk-Based Muffins in Children

Thumbnail

D2.07 - Cross-reactivity of Major Pollen Allergens in Spring in Beijing

Thumbnail

D2.08 - Extraction Efficiency Studies and Quantification of Major Peanut Allergens in Peanut Challenge Meals and Peanut Flour

Thumbnail

D2.09 - Qualitative concordance between two multiplex molecular diagnostic platforms in LTP allergy

Thumbnail

D2.10 - Early-onset cow’s milk protein and tree nut allergy: the value of component-resolved diagnosis in interpreting low-level alpha-gal sensitization

Thumbnail

D2.12 - Resolving heterophile antibody interference in the ISAC multiplex assay using HBT (Scantibodies)

Thumbnail

D2.13 - Migratory locust and house cricket as food allergy: cross reactivity or primary sensitivisation

Thumbnail

D2.14 - Component ratio analysis supports a targeted diagnostic approach in house dust mite allergy

Thumbnail

D2.03 - Cofactor-Dependent Anaphylaxis to Rosaceae and Citrus Fruits: Molecular Characterization Reveals High-Molecular-Weight Allergens Beyond Classical Panallergens

Thumbnail

D2.05 - Quail Egg Allergy with Independent Hen Egg Sensitization: Insights From Protein Profiling and Inhibition Assays

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to